Short Interest in COMPASS Pathways plc (NASDAQ:CMPS) Expands By 17.5%

COMPASS Pathways plc (NASDAQ:CMPS) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totalling 4,240,000 shares, a growth of 17.5% from the May 31st total of 3,610,000 shares. Based on an average trading volume of 497,900 shares, the days-to-cover ratio is currently 8.5 days.

COMPASS Pathways Stock Down 1.5 %

Shares of CMPS traded down $0.09 during mid-day trading on Monday, hitting $5.95. 315,738 shares of the company traded hands, compared to its average volume of 583,558. COMPASS Pathways has a 1-year low of $5.01 and a 1-year high of $12.75. The company has a quick ratio of 15.23, a current ratio of 15.23 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $406.86 million, a PE ratio of -2.51 and a beta of 2.28. The business has a 50 day moving average of $7.41 and a 200 day moving average of $8.87.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). Equities research analysts anticipate that COMPASS Pathways will post -2.24 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on CMPS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a report on Friday, June 21st. Morgan Stanley began coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They issued an “overweight” rating and a $30.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a report on Monday, May 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $47.40.

Insider Activity at COMPASS Pathways

In related news, major shareholder George Jay Goldsmith sold 23,881 shares of COMPASS Pathways stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the sale, the insider now directly owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.25% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On COMPASS Pathways

Large investors have recently bought and sold shares of the company. ARK Investment Management LLC boosted its position in COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after buying an additional 186,040 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in COMPASS Pathways in the 4th quarter worth approximately $4,812,000. Armistice Capital LLC purchased a new stake in COMPASS Pathways in the 3rd quarter worth approximately $2,960,000. Quest Partners LLC purchased a new stake in COMPASS Pathways in the 4th quarter worth approximately $33,000. Finally, Jump Financial LLC purchased a new stake in COMPASS Pathways in the 4th quarter worth approximately $371,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.